

470 Reed PCT/PTO 30 JUN 2000

FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

10806-129

U.S. APPLIC. NO. (if known, see 37 CFR 1.5)

09/582734

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/SE98/02463	30 DECEMBER 1998	30 DECEMBER 1997

TITLE OF INVENTION

ANALYTICAL METHOD COMPRISING ADDITION IN TWO OR MORE POSITIONS AND A DEVICE OR TEST KIT THEREFOR

APPLICANT(S) FOR DO/EO/US

MENDEL-HARTVIG, Ib; ZELIKMAN, Ilya; RUNDSTRÖM, Gerd

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau (22 July 1999).
 - c. is not required, as the application was filed in the United States Receiving Office (RO/JS)
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendment has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:


11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
 A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information: Copy of published International application, including Search Report

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label #: EL343337399US

Date of Deposit: 30 June 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box PCT; Assistant Commissioner for Patents; Washington, DC 20231.



U.S. APPLIC. NO. (if known, see 37 CFR 1.50) 09/582734	INTERNATIONAL APPLICATION NO. PCT/SE98/02463	ATTORNEY'S DOCKET NUMBER 10806-129		
		CALCULATIONS PTO USE ONLY		
17. The following fees are submitted:				
Basic National Fee (37 CFR 1.492(a)(1)-(5)): <input type="checkbox"/> Search Report has been prepared by the EPO or JPO <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) <input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) <input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)		\$840.00 \$670.00 \$760.00 \$970.00 \$96.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 970.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 130.00		
Claims	Number Filed	Number Extra	Rate	
Total Claims	33 -20 =	13	x \$18.00	\$ 234.00
Independent Claims	3 -3 =	0	x \$78.00	\$
Multiple dependent claim(s) (if applicable)		+ \$260.00		\$
TOTAL OF ABOVE CALCULATIONS =		\$1334.00		
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).		\$		
SUBTOTAL =		\$1334.00		
Processing fee of \$130.00 for furnishing the English translation later than the <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$		
TOTAL NATIONAL FEE =		\$1334.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+ \$		
TOTAL FEES ENCLOSED =		\$1334.00		
		Amount to be: refunded	\$	
		charged	\$	
a. <input checked="" type="checkbox"/> A check in the amount of \$1,334.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 04-1133.				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO: <u>Holly D. Kozlowski</u> SIGNATURE HOLLY D. KOZLOWSKI NAME 30,468 REGISTRATION NUMBER 30 JUNE 2000 DATE				

09/582734
430 Rec'd PCT/PTO 30 JUN 2000

Docket No. 10806-129

PATENT

CERTIFICATE OF MAILING

"Express Mail" mailing label #: EL343337399US

Date of Deposit: June 30, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box PCT; Assistant Commissioner for Patents; Washington, DC 20231.

Cathleen L. Vigil

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Ib MENDEL-HARTVIG et al : Paper No.:

Based On: PCT/SE98/02463 : Group Art Unit:

Filing Date: June 30, 2000 : Examiner:

For: **Analytical Method Comprising Addition in Two or More Positions and a Device or Test Kit Therefor**

PRELIMINARY AMENDMENT

BOX PCT
Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Prior to calculation of the filing fee and first action by the Examiner, please amend the present application as follows:

In the Claims:

Please amend claims 1-33 as follows:

Claim 1, line 20, replace "characterized in that" with --wherein--.

Claim 2, lines 1-2, replace "characterized in that" with --wherein--.

Claim 3, lines 1-2, replace "characterized in that" with --wherein--.

4. The method according to claim 1, wherein [any of the claims 1-3, characterized in that] Reactant* is pre-deposited in its application zone ($LZ_n''R^*$).

5. (Amended) The method according to claim 1, wherein [any of the claims 1-4, characterized in that] liquid_{n+1} is added to LZ_{n+1} before or substantially simultaneously with adding liquid_n to LZ_n , with the exception of n=m, which zone lacks the zone LZ_{n+1} .

6. (Amended) The method according to claim 1, wherein [any of the claims 1-5, characterized in that] LZ_{n+1} finishes where LZ_n starts, with the exception of n=m, which zone lacks the zone LZ_{n+1} .

7. (Amended) The method according to claim 1, wherein [any of the claims 1-6, characterized in that] application of liquid is performed substantially simultaneously in all $LZ_m \dots LZ_n \dots LZ_1$.

8. (Amended) The method according to claim 1, wherein [any of the claims 1-7, characterized in that] $m \leq 6$; n' is 1, 2 or 3, n" > n'; $LZ_{n'+1}$, $LZ_{n'+2}$, $LZ_{n'+3}$, $LZ_{n'-1}$, and $LZ_{n'-2}$ are application zones for liquids intended for transport of Reactant* or other reactant or buffer without reactant, as far as allowed by m, n" and n'.

9. (Amended) The method according to claim 1, wherein [any of the claims 1-8, characterized in that] at least one of the zones $LZ_m \dots LZ_n \dots LZ_1$ comprises a pad or material layer applied on the flow matrix.

10. (Amended) The method according to claim 1, wherein [any of the claims 1-8, characterized in that] the zones $LZ_m \dots LZ_n \dots LZ_1$ have zone spacers between each other.

11. (Amended) The method according to claim 1, wherein [any of the claims 1-10, characterized in that] the composition of transported components from an application zone LZ_n is not the same as from the nearest adjacent application zone LZ , in which flow is initiated, (LZ_{n+1} and LZ_{n-1} , with the exception of $n=m$ and $n=1$, which zones lack LZ_{n+1} and LZ_{n-1} , respectively).

12. (Amended) The method according to claim 1, wherein [any of the claims 1-11, characterized in that] at least one reactant, other than Reactant*, is pre-deposited in an application zone $LZ_n \dots R$ for liquid intended for transport of the reactant.

13. (Amended) The method according to claim 1, wherein [any of the claims 1-12, characterized in that] $m \leq 6$ and [that] n' for the application zone for sample ($LZ_n S$) is 1, 2 or 3.

14. (Amended) The method according to claim 1, wherein [any of the claims 1-13, characterized in that] Reactant* has biospecific affinity for the analyte so that Reactant* is incorporated into a complex Reactant'---Analyte---Reactant* in the detection zone in an amount related to the amount of analyte in the sample, in which complex Reactant' has biospecific affinity to the analyte and is

(a) Reactant I, or

(b) a reactant to which Reactant I exhibits biospecific affinity and which is transported from LZ_nS or from an application zone downstream of LZ_nS.

15. (Amended) The method according to claim 1, wherein [any of the claims 1-14, characterized in that] the matrix comprises at least one calibrator zone (CZ), in which calibrator is bound to, or in advance has been bound to the matrix.

Claim 16, lines 1-2, replace “characterized in that” with --wherein--.

17. (Amended) The method according to claim 1, wherein [any of the claims 1-16, characterized in that]

- a. the analyte is chosen among antigens generally, and
- b. the method is performed as part of diagnosing allergy or autoimmune disease.

Claim 18, line 18, replace “characterized in that” with --wherein--.

19. (Amended) The device according to claim 18, wherein [characterized in that] n" > n' and [that] the device is intended for sequential transport of analyte and Reactant*.

20. (Amended) The device according to claim 18, wherein [characterized in that] n" = n' and [that] the device is intended for simultaneous transport of analyte and Reactant*.

21. (Amended) The device according to claim 18, wherein [any of the claims 18-20, characterized in that] Reactant* is pre-deposited in its application zone (LZ_nR*).

22. (Amended) The device according to claim 18, wherein [any of the claims 18-21, characterized in that] LZ_{n+1} finishes where LZ_n starts, with the exception of $n=m$, which zone lacks the zone LZ_{n+1} .

23. (Amended) The device according to claim 18, wherein [any of the claims 18-22, characterized in that] $m \leq 6$; n' is 1, 2 or 3; $n'' > n'$; LZ_{n+1} , $LZ_{n'+2}$, $LZ_{n'+3}$, $LZ_{n'-1}$, and $LZ_{n'-2}$ are application zones for liquids intended for transport of Reactant* or other reactant or buffer without reactant, as far as allowed by m , n'' and n' .

24. (Amended) The device according to claim 18, wherein [any of the claims 18-23, characterized in that] the zones LZ_m . LZ_n . LZ_1 have zone spacers between each other.

25. (Amended) The device according to claim 18, wherein [any of the claims 18-23, characterized in that] at least one of the zones LZ_m . . LZ_n . . LZ_1 comprises a pad or material layer applied on the flow matrix.

26. (Amended) The device according to claim 18, wherein [any of the claims 18-25, characterized in that] at least one reactant, other than Reactant*, is pre-deposited in an application zone $LZ_n.R$ for liquid intended for transport of the reactant.

27. (Amended) The device according to claim 18, wherein [any of the claims 18-26, characterized in that] $m \leq 6$ and [that] n' for the application zone for sample ($LZ_n.S$) is 1, 2 or 3.

28. (Amended) The device according to claim 18, wherein [any of the claims 18-27, characterized in that] the detection zone DZ comprises firmly anchored Reactant I, and [that] a reactant to which Reactant I exhibits biospecific affinity optionally is pre-deposited in LZ_nS or in an application zone downstream of LZ_nS.

29. (Amended) The device according to claim 18, wherein [any of the claims 18-28, characterized in that] the flow matrix comprises at least one calibrator zone CZ, in which a calibrator or a binder for the calibrator is firmly anchored in the matrix.

30. (Amended) The device according to claim 29, wherein [characterized in that] the calibrator zone or zones (CZ) have a binder for the calibrator firmly anchored in the matrix, and [that] calibrator optionally is pre-deposited in the matrix upstream of the calibrator zone or zones.

31. (Amended) The device according to claim 18, wherein [any of the claims 18-30, characterized in that] the device is intended for diagnosing allergy or autoimmune disease.

32. (Amended) A test kit, [characterized in that the kit comprises] comprising (i) a device according to claim 18, [any of claims 18-29] and (ii) Reactant*.

Claim 33, lines 1-2, replace “characterized in that” with --wherein--.

REMARKS

By the present Amendment, the claims are amended to omit their multiple dependency and for several matters of form in accordance with customary U.S. patent practice. Since these changes do not involve any introduction of new matter, entry is believed to be in order and is respectfully requested.

Respectfully submitted,



Holly D. Kozlowski
Reg. No. 30,468
Dinsmore & Shohl LLP
1900 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

577905.01

ANALYTICAL METHOD COMPRISING ADDITION IN TWO OR MORE
POSITIONS AND A DEVICE AND TEST KIT THEREFOR

Technical field

5 The invention relates to a method for determination of an analyte in a sample by use of biospecific affinity reactants (Reactant 1, Reactant 2 etc.), one of which is analytically detectable (Reactant*) and one is firmly anchored in a detection zone in a transport flow matrix
10 (Reactant I). The sample (analyte) is transported by a flow in the matrix from one application zone for liquid (LZS) containing the analyte (sample) and/or a buffer, to the detection zone (DZ), in which Reactant I is firmly anchored. At the same time as the sample is transported in
15 the matrix the soluble reactants, including Reactant*, are also being transported. In the detection zone Reactant* is captured in an amount which is related to the amount of analyte present in the sample. To achieve this, Reactant* is chosen so that it may bind biospecifically directly to
20 Reactant I or indirectly via one or more added biospecific affinity reactants (including the analyte). The amount of analyte is then determined from the amount of Reactant* bound in the detection zone. The transport flow may contain zones, in which different biospecific affinity reactants
25 (e.g. Reactant*, but not analyte) have been applied in advance (predeposited) in order to be dissolved and transported along with the flow towards the detection zone.

By reactants (including the analyte), exhibiting
30 biospecific affinity (bioaffinity reactants), are meant individual members in the reactant pairs: antigen/hapten - antibody; biotin - avidin/streptavidin; two complementary single chains of nucleic acid etc. As antibodies antigen binding antibody fragments such as Fab, F(ab)₂', single
35 chain Fv antibodies (scFv) etc. are considered. Relevant reactants do not have to be naturally occurring but can also be synthetically produced molecules/binders.

The type of test methodology in question has previously been used primarily for biospecific affinity reactants where at least one part of an employed reactant pair has 5 exhibited protein structure, in particular in connection with so called immunochemical determination processes.

The biospecific affinity reactions are primarily performed in aqueous media (e.g. water).

10

The technique in question is well known and has often been applied to so called test strips, where the strip has functioned as a flow matrix. The flow has been initiated in the zone to which the sample has been added (LZS). The flow 15 has often been lateral, i.e. parallel to the surface of the matrix, or of other types, e.g. in depth in the matrix.

The test protocols have been of so called inhibition type (competitive) or non-inhibition type (non-competitive, 20 sandwich). See e.g. Behringwerke US 4,861,711; Unilever WO 88/08534; Abbot US 5,120,643; Becton Dickinson EP 234,232 and US 4,855,240; Abbot/Syntex US 4,740,468; Pharmacia AB, WO 96/22532, etc.

25 In this context one often mentions simultaneous and sequential methods (protocols) regarding certain reactants (especially analyte and Reactant*). In simultaneous variants analyte (sample) and the relevant reactant, e.g. Reactant*, are transported simultaneously into the 30 detection zone. Simultaneous variants may be obtained, if a sample is pre-incubated/mixed with Reactant* or if Reactant* has been predeposited in the sample application zone or in a zone downstream of the sample application zone but before the detection zone. In sequential variants the 35 analyte (sample) is transported before a reactant, e.g. Reactant*, into the detection zone. Sequential variants may be obtained, if the relevant reactant, e.g. Reactant*, is added to the same application zone as the sample after the

sample (analyte) has been transported out of the zone. A variant of sequential methodology is discussed in US 4,855,240 (Becton & Dickinson). As an alternative to the sample (analyte) being transported before "tracer"

5 (=Reactant*) in the same transport flow, US 4,855,240 describes separated transport flows, in which the time of transport is regulated such that sample (analyte) reaches the detection zone before the "tracer" (Reactant*).

10 The term simultaneous tests has often included every variant, in which sample and Reactant* are pre-incubated/mixed before being added to a flow matrix or in which sample is added to a flow matrix, in which Reactant* is predeposited in the sample application zone or

15 downstream thereof. The term sequential tests has similarly included every variant, in which Reactant* is added to the sample application zone after the sample has migrated out of its application zone. Thus, considerations have not been taken, concerning if the order of analyte and Reactant* is

20 changed during transport to the detection zone. If not otherwise stated, this nomenclature is also used for the present invention, but is now adapted so that there are several application zones for liquid. This view means that primarily the initial order is considered, when both

25 analyte and Reactant* are in soluble form, and not the order in which analyte and Reactant* are transported into the detection zone.

Disadvantages with prior art and objects of the invention.

30 The prior art has often involved practical problems on automation, primarily because pre-incubation or sequential addition of sample and reactants have often been required, often in a certain predetermined order defined by the test protocol used. The object of the invention is to (a)

35 facilitate automation, (b) avoid sequential addition of sample and the analytically detectable reactant (Reactant*), and (c) allow for pre-deposited Reactant* when using sequential methodology, which relates to analyte and

Reactant*. More general aims are to achieve high quality test results, preferably with improved sensitivity and precision than given by previous variants.

5 The invention

Surprisingly we have now discovered that if flow is initiated by almost simultaneous addition of liquid to two adjacent zones in a flow matrix, the liquid added in the downstream zone migrates before the liquid which has been 10 added in the upstream zone in direction towards the detection zone. Our discovery involves that zonewise migration of liquids may also be obtained if addition of liquid in an upstream zone is performed after addition of liquid in the nearest downstream zone. By applying this 15 discovery on the relevant type of analysis methods, improvements can be obtained regarding the objects stated above.

A first main aspect of the invention relates to the 20 initially mentioned analysis methods and is characterized in that

A. the flow matrix exhibits at least two application zones for liquid arranged substantially adjacent to each other:

25

LZ_m . . . LZ_n . . . LZ₁ DZ
----->

wherein

30 a) LZ_n is an application zone for liquid, where n is the position of the application zone LZ_n (n is an integer $2 < n \leq m$)
b) m is the total number of application zones, in which flow is initiated,
35 c) one LZ_n is an application zone for sample (LZ_n, S) and one LZ_n is application zone for Reactant* (LZ_n, R*) with $n'' \geq n'$,

- d) -----> is the direction of the flow, and
- e) DZ is detection zone, and

B. flow is initiated by adding liquid to each zone

5 LZ_m . . LZ_n . . LZ₁ in such a way that liquid_{n+1}, added to the application zone LZ_{n+1}, is transported through the matrix after liquid_n, added to the nearest downstream application zone LZ_n.

10 Liquid_{n+1} may easily migrate immediately after liquid_n, if the corresponding zones for application of liquid are adjacent to each other or if added liquid volumes are adapted for this aim.

15 In the most common case the above mentioned involves adding liquid_{n+1} to LZ_{n+1} before or primarily simultaneously with adding liquid_n to LZ_n. For n = m, LZ_{n+1} is lacking, and for that zone it is therefore not possible to add any liquid to LZ_{m+1}. Practical advantages are achieved if the addition is 20 performed primarily simultaneously for all LZ_m . . LZ_n . . LZ₁.

The number (m) of application zones for liquid (LZ_m . . LZ_n . . LZ₁) may in principle be any number with 25 the exception of one (m ≠ 1). For practical reasons it is likely that in the future 2 ≤ m ≤ 10, preferably 2 ≤ m ≤ 6, such as m = 2 or 3 or 4 or 5.

The liquids added (liquid₁ . . . liquid_m) may consist of 30 only buffer solution or buffer solution plus a reactant (Reactant 1, Reactant 2 etc.), needed to make it possible for Reactant* to be captured in the detection zone in an amount related to the amount of analyte in the sample. Also Reactant* may be included in a liquid_n. As a rule the 35 composition of transported components from an application zone is not the same as from the nearest adjacent application zone, in which flow is initiated (LZ_{n+1} and LZ_{n-1})

with the exception of $n = m$ and $n = 1$ for which the zones LZ_{n+1} and LZ_{n-1} , respectively, are lacking).

By the expression "substantially adjacent to each other" is
5 meant that the application zones for liquid are immediately
adjacent to each other or with an intermediate area of
matrix which preferably is no more than about 2 mm, and
particularly no more than about 1 mm.

10 A liquid added in an application zone may have a tendency
to spread on top of the matrix to parts of the matrix being
outside the zone. For adjacent zones this means that
liquids may be mixed with each other in an undesired way.

To avoid this, physical barriers delimiting two adjacent

15 application zones (zone spacers) are placed. The barriers
should primarily be placed on top of the matrix, but may be
extended down into the matrix without completely quenching
the flow. Delimitation is primarily against an adjacent
zone for application of liquid, but can of course extend

20 around a whole application zone for liquid. Liquid may also
be introduced via pads or material layers applied on the
matrix and from the same or a different material than the
matrix material. In such a case there is no need for zone
spacers.

25

Relevant reactants may be predeposited in an application
zone for liquid (LZ_n) or between two such zones. An
application zone for liquid, only intended for transporting
buffering components and/or other components not

30 participating in the biospecific affinity reactions (i.e.
liquid neither containing nor intended for transport of any
reactant or analyte), is called LZ_nB below. An application
zone for liquid (LZ_n), where the liquid contains a reactant
or is intended for transport of a reactant, e.g. Reactant*,

35 Reactant 1, Reactant 2 etc., is called $LZ_n...R*$, $LZ_n...R1$,
 $LZ_n...R2$ etc. below. If a liquid_n is to transport a
combination of components, e.g. Reactant* and analyte
(sample) the application zone will be common for the

components and will be designated LZ_n...R2/R1 etc. For the combination sample and Reactant*, the application zone will be LZ_n.R*/S (n' = n''). That liquid_n is intended for transport of a certain reactant includes that the reactant 5 in question also can be predeposited in the zone LZ_n. The latter includes that the reactant may be predeposited in an area downstream of the application zone for the relevant liquid but upstream of the nearest downstream located LZ (LZ_{n-1}), or if n = 1 only upstream of the detection zone (as 10 LZ_{n-1} then is lacking).

By predeposition is meant that a reactant is added in advance to the matrix and in a way so as not to spread in the matrix until it is reached by liquid, which has been 15 applied to initiate flow. Predeposition of reactants may be performed in a way known per se. (See e.g. Behringwerke US 4,861,711; Unilever WO 88/08534; Abbot US 5,120,643; Becton Dickinson EP 284,232). It is important that arrangements are made so that the reactant in question is quickly 20 dissolved, when liquid passes through an area, containing predeposited reactant. In order to achieve quick dissolution it has been common to incorporate reactants in substances that as such dissolve quickly. This type of substances are often hydrophilic with polar and/or charged 25 groups, such as hydroxy, carboxy, amino, sulphonate etc. In particular there may be mentioned hydrophilic quickly soluble polymers, e.g. having carbohydrate structure, simple sugars including mono-, di- and oligosaccharides and corresponding sugar alcohols (mannitol, sorbitol etc.). It 30 is common practice to first coat the application zone in question with a layer of the quickly soluble substance, and then the reactant is applied, optionally followed by one additional layer of quickly soluble substance. An alternative way is by incorporating the reactant in 35 particles of quickly soluble material which then are deposited in the relevant zone of the matrix.

Some of the most important embodiments regarding the application zones for liquid may be summarized: $2 \leq m \leq 6$; n' is 1, 2 or 3; $n'' > n'$ or $n'' = n'$; $LZ_{n,S}$ is the application zone for sample and optionally also for

5 Reactant* or other reactant; $LZ_{n'+1}$, $LZ_{n'+2}$, $LZ_{n'+3}$, $LZ_{n'-1}$, and $LZ_{n'-2}$ are application zones for liquids intended for transport of Reactant* or other reactant or buffer without reactant as far as allowed by m , n'' and n' .

10 Transport flow through the particular types of matrix may be achieved by the action of capillary forces, e.g. by starting with a substantially dry matrix. A sucking body may be placed at the end of the flow as an aid. Flow, meaning transport of primarily only dissolved components,

15 may be achieved if an electrical field is applied across the matrix.

Test protocols

By use of the invention reactants and analyte can be made

20 to migrate zonewise as individual components or together in different combinations towards the detection zone. The exact sequence of application zones is determined by the test protocol to be utilized.

25 The invention may be applied to competitive (inhibition) as well as non-competitive (non-inhibition) test variants irrespective of if these are simultaneous or sequential regarding any reactant. Illustrative systems are shown schematically below in form of the complexes formed. "-"

30 relates to firm anchoring to the matrix, "---" relates to binding via biospecific affinity. For the sake of simplicity it has been assumed that reactants used are monovalent regarding utilized binding sites.

A. Sandwich protocol (non-inhibition)

Reactant I and Reactant* both have biospecific affinity for the analyte. x = number of moles of Reactant I on the matrix and y = number of moles of analyte (= number of 5 moles of Reactant*), bound to Reactant I.

Complex in the detection zone:

Matrix (-Reactant I)_{x-y} (-Reactant I --- analyte --- Reactant*)_y

10

Simultaneous variants:

m = 2: LZ₂R*/S LZ₁B DZ

Sequential variants:

15 m = 2: LZ₂R* LZ₁S DZ.

m = 3: LZ₃R* LZ₂B LZ₁S DZ and alternatives where the buffer zone has position 1 or 3.

m = 4: LZ₄B LZ₃R* LZ₂B LZ₁S DZ and alternatives where any of the buffer zones is placed in position 1.

20 m = 5: The same sequence as for m = 4 with the exception that an extra buffer zone is placed in position 1.

B. Sandwich protocol (non-inhibition):

Reactant I exhibits biospecific affinity for Reactant II.

25 Both Reactant II and Reactant* have biospecific affinity for the analyte. x = number of moles of Reactant I on the matrix, y = number of moles of analyte (= number of moles of Reactant*), bound to Reactant I via Reactant II. y + z is the number of moles of Reactant II bound to Reactant I.

30

Complex in the detection zone:

Matrix (-Reactant I)_{x-z-y} (-Reactant I --- Reactant II)_z (-Reactant I --- Reactant II --- analyte --- Reactant*)_y

35 Simultaneous variants:

m = 2: The same as for protocol A with the exception that LZ₂R*/S is LZ₂R*/S/RII or that LZ₁B is LZ₁RII.

m = 3: LZ₃R*/S LZ₂B LZ₁RII DZ or

10

LZ₃R*/S LZ₂RII LZ₁B DZ.Sequential variants:

m = 2: The same as for protocol A with the exception that

5 LZ₁S is replaced by LZ₁S/RII.m = 3: LZ₃R* LZ₂B LZ₁S/RII DZ orLZ₃R* LZ₂S LZ₁RII DZ orLZ₃R* LZ₂S/RII LZ₁B DZ.

m = 4, 5, 6: In analogy with protocol A sequences with up

10 to 6 application zones for liquid may be considered.

C. Inhibition protocol:

Reactant I is an analyte analogue, firmly anchored to the matrix, Reactant III exhibits biospecific affinity for the

15 analyte and Reactant* has biospecific affinity for Reactant III. x = number of moles of Reactant I on the matrix. y = number of moles of Reactant III (= number of moles of Reactant*), bound to the matrix via Reactant I. The conditions are selected so that y is a measure of the 20 amount of analyte in the sample.

Complex in the detection zone:Matrix (-Reactant I)_{x-y} (-Reactant I --- Reactant III --- Reactant*)_y

25

Simultaneous variants:m = 2: LZ₂R*/RIII/S LZ₁B DZ.Sequential variants:30 m = 2: LZ₂R* LZ₁/RIII/S DZ.

m = 3, 4 and 5: May be built up in analogy with protocol A.

D. Inhibition protocol

Reactant I exhibits biospecific affinity for both Analyte

35 and Reactant*. Reactant* is a soluble analyte analogue. x + y is the number of moles of Reactant I on the matrix, x and y are the number of moles of Reactant* and Analyte, respectively, being bound to the matrix.

Complex in the detection zone:

Matrix (-Reactant I --- Reactant*)_x (-Reactant I ---
Analyte)_y:

5

Simultaneous variant:

$m = 2: LZ_2R^*/S LZ_1B DZ$

Sequential variant:

10 $m = 2: LZ_2R^* LZ_1S DZ$

$m = 3, 4$ and 5 may be built up in analogy with protocol A.

Matrices

The matrix defines the space in which the flow is
15 transported. The matrix may be the inner surface of a
simple flow channel (e.g. a capillary), the inner surface
of a porous matrix having a system of flow channels (porous
matrix) etc. extending through. For the sake of simplicity,
matrices, usable in this variant of the invention, will be
20 called flow matrices. Porous matrices may exist in the form
of monoliths, sheets, columns, membranes, single flow
channels having capillary dimensions or aggregated systems
of such flow channels etc. They may also exist in the form
of particles packed in column casings, compressed fibres
25 etc. The inner surface of the matrices, i.e. the surface of
the flow channels, should be hydrophilic, such that aqueous
media (usually water) may be absorbed and transported
through the matrices. The smallest inner dimension of the
flow channels should be sufficiently large for allowing
30 transport through the matrix of the reactants being used.
The rule of thumb is that suitable matrices are selected
among those having flow channels with the smallest inner
dimension (often as a diameter for round channels) in the
interval 0.4-1000 μm , preferably 0.4-100 μm if the matrix
35 exhibits a system of mutually communicating flow channels.
Flow channels having a smallest inner dimension in the
upper part of the interval 0.4-1000 μm are primarily of

interest for simple unbranched channels, through which flow is driven by an externally imposed pressure or suction.

Relevant matrices are often built up from a polymer, e.g.

5 nitrocellulose, nylon etc. The material in the matrix as well as the physical and geometrical design of the flow channels may vary along the flow depending on what a certain part of the matrix is to be used for (Pharmacia AB WO 96/22532; Medix WO 94/15215).

10

Detection zone

In the detection zone, Reactant I is firmly anchored to the matrix with bonds not allowing unintentional transport of Reactant I under the test conditions. Attachment of

15 Reactant I to the matrix may be covalent, via physical adsorption, via biospecific affinity etc. Like prior art in this field the invention may utilize combinations of binding types, e.g. covalent binding to the matrix of a biospecific affinity reactant directed to Reactant I. In

20 particular may be mentioned a matrix exhibiting a physically adsorptively or covalently bound member of a specific binding pair (reactant pair) in combination with Reactant I coupled or conjugated to the other member of the specific binding pair, or a matrix exhibiting a similarly

25 bound antibody directed to Reactant I. As examples of specific binding pairs may be mentioned immunological binding pairs, such as antigen-antibody and haptene-antibody, biotin-avidin or -streptavidin, lectin-sugar, hormone-hormone receptor, nucleic acid duplex. If reactant

30 I binds to the matrix via another reactant according to the above, Reactant I need not be immobilized in the matrix but may either be movably (diffusively) predeposited in the matrix in an area or zone that is separated from the detection zone, or it may be added together with or

35 separately from the sample. Anchoring of Reactant I to the matrix may be achieved via particles having been deposited in/on the matrix and to which Reactant I is covalently, physically adsorptively or biospecifically etc. bound. The

PCT/SE98/02463

particles attach to the matrix either because their size has been selected such that they cannot be transported through the matrix or via physical adsorption. See inter alia Abbott/Syntex US 4,740,468; Abbott EP 472,376; 5 Hybritech EP 437,287 and EP 200,381; Grace & Co. EP 420,053; Fuji Photo Film US 4,657,739; Boehringer Mannheim WO 94/06012. For the invention the latter variant with smaller particles adsorbing physically to the matrix has been shown to be good.

10

In one and the same transport flow there may be several detection zones (DZ1, DZ2 etc.). One or more of the detection zones may relate to the same or different analytes. If the analytes are different Reactant I is 15 usually different for each DZ.

Analytically detectable reactant (Reactant*)

In the invention Reactant* cannot be an analyte. Usually analytical detectability is obtained because a natural 20 reactant, e.g. an antibody or an antigen or a hapten, is provided with an analytically detectable group. Well known examples of often used groups are enzymatically active groups (enzyme, co-factor, co-enzyme, enzyme substrate etc.), fluorogenic, chromophoric, chemiluminiscent, 25 radioactive groups etc. Groups being detected by means of a biospecific affinity reactant usually also are referred to this category, e.g. biotin, hapten, class-, subclass- and species-specific determinants in immunoglobulins etc.

30 A preferred label group is particles optionally containing any of the detectable groups above, such as fluorophoric groups or chromogenic groups (coloured particles). Useful particles often have a size in the interval of 0.001-5 μm . The particles may have colloidal dimensions, so called sol 35 (i.e. usually spherical and monodisperse having a size in the interval 0.001-1 μm). Especially metal particles (e.g. gold sol), non-metal particles (e.g. SiO_2 , carbon, latex

and killed erythrocytes and bacteria) may be mentioned. Also particles of non-colloidal dimensions but with focus on non-sedimenting capability have been used. These have been more or less irregular and more or less polydisperse 5 (carbon particles < 1 μm ; Pharmacia AB, WO 96/22532).

For particles as label group reference is made to Unilever WO 88/08534; Abbott US 5,120,643; Becton Dickinson EP 284,232 among others.

10

In connection with the development that has led to the present invention it was surprisingly found that good results may be obtained if one simultaneously utilizes:

15 (a) Reactant* with label particles according to the above as a detectable group, and

15 (b) a detection zone, in which Reactant I has been anchored to the matrix via particles substantially 20 having dimensions that would allow transport of the particles as such through the matrix.

We have achieved functioning systems, in which label particles and anchoring particles substantially have the 25 same dimensions. This means with great probability that the label particles may be larger than the anchoring particles and vice versa, as long as they remain smaller than the flow channels defined by the matrix. The system may function with or without pre-deposition of Reactant* in the 30 intended application zone. This embodiment is part of an invention, described in our co-pending PCT application: "Analytical method using particles and test kit for performing the method" (based on SE 9704935-7). This separate patent application is incorporated herein by 35 reference.

Analytes

The invention is primarily adapted for determination of biospecific affinity reactants of the types initially mentioned. The reactants may be a cell or a virus or a part 5 thereof. In particular antigen, such as an immunoglobulin or an antibody may be mentioned. For immunoglobulins the determination may relate to a certain Ig and/or certain Ig subclass. For antibodies the determination may relate to a certain specificity, optionally also the Ig class or the Ig 10 subclass of the antibody. Relevant Ig classes are IgA, IgD, IgE, IgG and IgM. Relevant Ig subclasses are IgG1, IgG2, IgG3 and IgG4.

In sandwich variants (according to protocols A and B, 15 above) the analyte may be an antibody, directed to an allergen/antigen/hapten and be derived from a certain species, a certain Ig class or a certain Ig subclass. In this case Reactant* may be an analytically detectable antibody directed to an epitope specific for the species, 20 Ig class or Ig subclass and with Reactant I (protocol A) or Reactant II (protocol B) as the allergen/antigen/hapten. Alternatively the reverse may be selected, i.e. Reactant* is the allergen/antigen/hapten and Reactant I and Reactant II, respectively, is the antibody, directed to the analyte. 25 When the analyte is an antigen in general, both Reactant I and Reactant* may be antibodies, directed to the antigen, in protocol A. For protocol B it is Reactant II and Reactant* that are antibodies directed to the antigen.

30 Competitive variants are most interesting for low molecular analytes. Illustrative examples are antigen and hapten. For protocol C Reactant I may be the antigen or the hapten, firmly anchored to the matrix, Reactant III may be an antibody, directed to the antigen, and Reactant* may be an 35 antibody, directed to Reactant III. For protocol D Reactant I may be an antibody directed to the analyte and Reactant* may be the analyte labelled with an analytically detectable group.

The method of the invention may be performed as part of diagnosing allergy or autoimmune disease.

5 For the inventors it has been of special interest to measure anti-allergen antibodies of IgE or IgG class, for the latter preferably with focus on any of the subclasses mentioned. Measuring of allergen-specific antibodies can be utilized when diagnosing IgE mediated allergy.

10

Samples

Relevant samples may be of biological origin, e.g. from different body fluids (whole blood, serum, plasma, urine, saliva, tear fluid, cerebrospinal fluid etc.), from cell

15 culture media, processing procedures in biotechnology, from tissue extracts, from food stuff, from the environment (environmental analysis samples) etc. The samples may be pretreated in order to fit e.g. the matrix, the test protocol involved etc.

20

Calibrators

Determination methods of the type that the invention is related to, involve that the detectable signal from the analytically detectable reactant (Reactant*) is measured

25 and the measured signal (sample value) is taken as a measure of the amount of analyte present in the sample. To transfer the measurement signal to actual amounts of analyte the signal is usually compared to the corresponding signal (calibrator value) of known standard amounts of
30 analyte (calibrators). In connection with the present invention a new calibrator system has been developed, which applied to the present invention constitutes a best embodiment.

35 This separate invention means that the used calibrator in advance has been anchored to a matrix (matrix calibrator), preferably of the same type as the one utilized for sample run. When measuring calibrator values, matrix calibrator is

allowed to bind to Reactant*, and then the measurement signal from Reactant* is measured in a way known per se. By utilizing different amounts of matrix calibrator a series of calibrator values may be obtained corresponding to 5 different pre-determined amounts of analyte in sample (standard amounts, dose-response curve, calibration curve).

Alternatively, instead a binder for the calibrator has been anchored to the matrix, and calibrator is added at the 10 determination of calibrator value, optionally pre-deposited in the matrix upstream of the calibrator zone(s) to be dissolved by sample solution or buffer at the determination. When a calibrator binder is bound to the matrix, the calibrator may either be movably (diffusively) 15 pre-deposited in the matrix in a zone separated from the detection zone, or be added together with or separately from the sample. The calibrator binder is usually one member of a specific binding pair (reactant pair), the other member of the binding pair being coupled or 20 conjugated to the calibrator substance. As examples of such specific binding pairs may be mentioned immunological binding pairs such as antigen-antibody and haptene-antibody, biotin-avidin or -streptavidin, lectin-sugar, hormone-hormone receptor, nucleic acid duplex.

25 Applied to the present invention our new calibrator system involves primarily that the transport flow passes one or more zones with a calibrator, firmly anchored to the matrix in the respective calibrator zone (CZ).

30 Anchoring of a calibrator to the matrix in a calibrator zone may be performed according to the same principles as for anchoring of Reactant I to a detection zone.

35 Calibrator zones should be located downstream of an application zone for liquid, intended for transport of Reactant*. In relation to the detection zone (DZ) the calibrator zone is preferably located upstream.

Our invention relating to calibrators is described in detail in our co-pending PCT application with the title "Method using a new calibrator and a device and test kit including the calibrator" (based on SE 9704933-2). This application is incorporated herein by reference.

A second main aspect of the invention

The flow matrix according to the above containing two or 10 more application zones for liquid, optionally in the form of a kit wherein the flow matrix is comprised together with the analytically indicatable reactant, constitutes a second main aspect of the invention.

15 The invention is illustrated in the following non-limiting experimental part.

**EXAMPLE 1: SEQUENTIAL METHOD WITH THE ZONE SEQUENCE: LZ₄B,
LZ₃R*, LZ₂B, LZ₁S, DZ. DETECTION OF hIgE IN TEST VARIANT
20 WITH CARBON PARTICLE CONJUGATE**

Methods and materials

Adsorption of phenyldextran to polystyrene particles:

Phenyldextran (substitution degree: 1 phenyl group on each 25 fifth monosaccharide unit = 20%, Mw dextran 40,000, Pharmacia Biotech AB, Uppsala, Sweden) was adsorbed to polystyrene particles (0.49 µm Bangs Laboratories, USA) by incubations under stirring with phenyldextran dissolved in deionized water to 1) 5 mg/ml, 10% particle suspension, RT 30 30-60 minutes; 2) 5 mg/ml, 5% particle suspension, RT 1 h; 3) 20 mg/ml, 1-2% particle suspension, RT 3 h or overnight. The particles were subsequently washed twice with deionized water. The particle suspensions were centrifuged between 35 each incubation and wash (12,100xg, 25 min, Beckman, J-21, JA-20, 10,000 rpm). The particle suspension was finally sonicated (Ultrasonic bath, Branson 5210, 5 min).

Coupling of anti-human IgE antibody (anti-hIgE) to polystyrene particle: Anti-hIgE was coupled to phenyldextran coated polystyrene particles with CDAP (1-cyano-4-dimethylamino-pyridinium bromide (Kohn J and

5 Wilchek M, FEBS Letters 154(1) (1983) 209-210).

Desalting and change of buffer of anti-hIgE was performed by gel filtration (PD-10, Pharmacia Biotech AB) in NaHCO_3 , 0.1 M, pH 8.5. 2.3 g of polystyrene particles (coated with 10 phenyldextran according to above) in 2% solution in 30% (by volume) acetone were activated with 17 ml CDAP (0.44 M) and 14 ml TEA (0.2 M triethylamine, Riedel-deHaën, Germany). CDAP was added with stirring for 150 seconds and TEA for 150 seconds. The particles were washed with 30% (by volume) acetone and centrifuged at 12,100xg (25 min, Beckman, J-21, JA-20, 10,000 rpm). 17 of anti-hIgE was coupled to the activated particles (2%, 0.15 g in 0.1 M NaHCO_3 , pH 8.5) in incubating with stirring overnight at +4°C. The particles were centrifuged and decanted before deactivating with 20 glutamic acid 0.05 M and aspartic acid 0.05 M in 0.1 M NaCHO_3 , pH 8.5 when incubating with stirring overnight at +4°C. Coupled particles were washed once with 0.1 M NaHCO_3 , 0.3 M NaCl, pH 8.5, once with 0.1 M HAc, 0.3 M NaCl pH 5, once with 0.1 M NaHCO_3 , pH 8.5 and once with 20 mM borate 25 buffer pH 8.5.

The concentration of particles was determined spectrophotometrically at A_{600} nm with untreated particles as reference. Concentration of coupled protein was 30 determined by having anti-hIgE present during the coupling and cpm measurement.

Carbon particle conjugate (Reactant*): This was prepared by anti-hIgE being adsorbed to carbon particles (sp100, < 1 35 μm , Degussa, Germany) according to WO 96/22532 (Pharmacia AB). The final solution used in the flow matrix contained 400 μg of carbon particles per ml.

Deposition of anti-hIgE-coupled particles on membrane: On nitrocellulose sheets (Whatman, 8 μ m, length 5 cm and width 25 cm with polyester backing, anti-hIgE particles (prepared 5 according to the above) were deposited in a zone over the width of the sheet (future detection zone) with Linear Striper (IVEK Corporation). The flow was 1 μ l/sec and 1 μ l/cm. The particles were diluted in borate buffer (20 mM, pH 8.5, Dextran T5000 4.2% w/w, sorbitol 5.8% w/w). The 10 amount of deposited anti-IgE antibody was about 1000 ng/cm. The sheets were dried for 1 h at 30°C.

Zones for application of buffer, sample and carbon particle conjugate: Well separated from the zone, containing 15 deposited material, 4 Inplastor strips (Mylar with glue on one side, Gelman) with a width of 1 mm were placed in parallel with the zone and parallel with each other at a distance of 5 mm from each other (zone spacers). The Inplastor strips thus defined four zones with a width of 5 20 mm. The sheets were cut perpendicularly relative to the zone containing deposited material, to strips with a width of 0.5 cm (the length of the strip then became 5 cm) (Singulator: Matrix 1201 membrane cutter, Kinematic automation). The final strips exhibited four parallel zones 25 (application zones) separated by Inplastor strips as zone spacers and a separate zone with deposited anti-hIgE antibody (detection zone). As a comparison strips without zone spacers, i.e. without separated application zones were produced.

30

Test methodology: Strips with separated application zones were mounted on a plane holder. At the top (0.5 cm) of the strip (and with the detection zone as the nearest zone) a sucking membrane was placed (Whatman, 17 Chr, width 3 cm). 35 The holder also gave a constant pressure on the sucking membranes. For simultaneous application of reagents to the four subzones a 4 channel Multipipette (Labsystems) was

used. The multipipette was loaded so that serum sample (30 μ l) was applied in the application zone nearest to the detection zone in the order of buffer (30 μ l), carbon particle conjugate (30 μ l) and buffer (30+30 μ l) in the respective upstream application zone. For sequential application to the strips without zone spacers, 30 μ l of sample were first applied to the lower end of the strip. After suction of sample volume, buffer (30 μ l), carbon particle conjugate (30 μ l) and buffer (30+30 μ l) were added successively after suction. The carbon particle conjugate was prepared according to above and suspended in buffer. The buffer was NaPO₄ 0.1 M, BSA 3%, NaN₃ 0.05%, sucrose 3%, sodium chloride 0.2%, phenyldextran 0.05%, bovine gammaglobulin 0.05%, pH 7.5. The binding of the carbon particle conjugate to the detection zone was quantitated by measuring of absorbance (Ultroscan XL, Enhanced Laser Densitometer, LKB). IgE with standard concentrations in plasma environment (0; 0.5; 2; 10; 50, and 200 KU/L) was used as samples.

20

Results

Having four application zones for liquid and simultaneous addition, the liquids were migrating in the order of the application zones, i.e. the sample being in the zone nearest to the detection zone was migrating first, without being mixed with the washing solution of the following application zone, which solution in turn started migrating, when the sample had been transported out of the application zone for samples. Correspondingly the liquids of the remaining zones were migrating sequentially without being mixed.

Table 1: Analysis results from runs with sequential addition in one zone and from simultaneous addition in four subzones (buffer, analytically detectable reactant, buffer, sample).

IgE KU/L	Sequential	Simultaneous
	addition in one zone	addition in 4 subzones
0,5	0	12
2	312	207
10	1241	831
50	1921	1560
200	2115	2044

In Table 1 is shown that the uptake decreases slightly for

5 strips with discrete application zones compared to when addition is performed in one and the same zone. The decrease is, however, marginal. Therefore the experiment shows that generally the same result may be achieved if simultaneous addition is performed to the zone sequence
10 LZ₄B, LZ₃R*, LZ₂B, LZ₁S as if sample, Reactant* and buffer are added sequentially to a common application zone.

If a firmly anchored anti-IgE antibody (Reactant I) is replaced by an allergen a determination method for IgE
15 antibodies directed to the allergen is obtained.

Analogously, test systems related to antibodies of another class/subclass and with another specificity may be determined. Application zones for only buffer may be omitted. For additional alternative test protocols and
20 analytes see above under the headings "Test protocols" and "Analytes".

EXAMPLE 2: SEQUENTIAL METHOD WITH THE ZONE SEQUENCE: LZ₄B,
LZ₃R*, LZ₂B, LZ₁S, DZ. DETECTION OF hIgE IN TEST VARIANT
WITH FLUORESCENT DETECTION CONJUGATE

5 Methods and materials

Coupling of anti-human IgE antibody (anti-hIgE) to a polystyrene particle: Anti-hIgE was coupled to polystyrene particles coated with phenyldextran (prepared according to Example 1) with CDAP (1-cyano-4-dimethylaminopyridinium bromide) (Kohn J and Wilchek M, FEBS Letters 154(1) (1983) 209-210). Desalting and buffer change of anti-hIgE was performed by gel filtration (PD-10, Amersham Pharmacia Biotech AB) in NaHCO₃, 0.1 M, pH 8,5.

15 0.35 g of polystyrene particles (2% solution) were activated with 5.2 ml of CDAP (0.44 M) and 4.2 ml of TEA (0.2 M triethylamine, Riedel-deHaën, Germany). CDAP was added with stirring for 60 seconds and TEA for 120 seconds. A five times excess of ice-cooled deionised water was added. The particles were centrifuged at 12,100xg (25 min., Beckman, J-21, JA-20, 10,1000 rpm). The resulting pellet was dissolved in ice-cooled, deionized water and washed once with ice-cooled deionized water and then centrifuged at 12,000 x g. 50 mg of anti-hIgE were coupled to the activated particles (2%, 0.35 g in 0.1 M NaHCO₃, pH 8.5). Incubation with stirring was performed for 1 hour at +4°C. After centrifugation, the particles were deactivated with glutamic acid, 0.05 M, and aspartic acid, 0.05 M in 0.1 M NaHCO₃, pH 8.5. Incubation and stirring was then performed overnight at +4°C. Coupled particles were washed twice with 20 mM borate buffer, pH 8.5, whereupon the particle concentration was determined spectrophotometrically at A_{600nm} with untreated particles as reference. Coupled protein concentration was determined by having radioactive anti-hIgE present during the coupling.

Coupling of anti-hIgE antibodies to detection particles:

Antibodies to hIgE cleaved with pepsin to fab'2 fragments were coupled to fluorescent polystyrene particles having aldehyde groups on their surface (Molecular Probes C-17177

5 TransFluoSphere, aldehyde-sulphate microspheres, 0.1 μ m, 633/720, 2% solids). 23 mg of antibody were then coupled to 66 mg of particles in 50 mM NaPO₄, pH 6.5, overnight at room temperature, whereupon 205 μ L of NaCNBH₄ (5 M) were added to reduce the coupling for 3 hours at room
10 temperature. Centrifugation was performed at 20,800 x g for 50 minutes (50 minutes in Eppendorf 5417R, 14,000 rpm), and deactivation in glutamic acid, 0.05 M, and aspartic acid, 0.05 M, in deionized water, pH 6.5, was then performed overnight with stirring at room temperature. After
15 centrifugation again at 20,800 x g, blocking was performed with 0.2% BSA in 50 mM NaPO₄, pH 7.4, with 0.05% NaN₃ and incubation was carried out overnight at +4°C. Centrifugation was then performed again at 20,800 x g and washing was performed twice with blocking buffer which was
20 then used also for storage. The particle concentration was determined in a fluorimeter (Perkin-Elmer LS50B) with a standard curve prepared with the original particle. Coupled protein concentration was determined by having radioactive hIgE present during the coupling.

25

Deposition of anti-hIgE-coupled particles on membrane and application zones: Was performed according to Example 1, except that the Inplastor strips were replaced by strips of adhesive tape (2 mils clear polyester Arcare with glue on
30 one side).

Test methodology: Strips with spaced application zones were mounted to an inclined plane, about 16°, in a holder. At the top (0.5 cm) of the strip (and with the detection zone
35 as the nearest zone), two sucking membranes (Whatman, 17 Chr, width 3.4 cm) were placed on top of each other. The holder also exerted a constant pressure on the sucking

membranes. For simultaneous application of reagents to the four subzones, a multichannel Finn pipette (Labsystems) was used. The multipipette was charged so that serum sample (30 μ L) was applied to the application zone nearest to the

5 detection zone in the order of buffer (15 μ L), fluorescent particle conjugate (30 μ L) and buffer (30 + 30 μ L) in the respective application zone located upstream. For sequential application to the strips without zone spacer, 30 μ L of sample were first applied to the lower end of the

10 strip. After sucking of the sample volume, buffer (15 μ L), detection particle conjugate (30 μ L) and buffer (30 + 30 μ L) were successively added after sucking. The particle conjugate was suspended in assay buffer consisting of NaPO₄ 0.1 M, BSA 3 %, NaN₃ 0.05 %, sucrose 10 %, NaCl, 0.15 M,

15 bovine gammaglobulin 0.05 %, pH 7.5. The measurement of time started with the application of the sample, and the time until the last buffer had been sucked into the membrane was noted. The binding of the fluorescent particle conjugate to the detection zone was quantified by scanning

20 with a red diode laser (635 \pm 5 nm). As sample were used IgE standard concentrations in plasma environment (0, 0.5, 2, 10, 50 and 200 KU/L).

Results:

25 Precisely as in Example 1, the liquids migrated out of the application zone in the existing order. The time for a whole test with simultaneous application was about 20 minutes, and the time for a test with sequential application was about 25 minutes.

30

Table 2: Analysis results from runs with sequential application in one zone and from simultaneous application in four subzones (buffer, analytically detectable reactant, buffer, sample).

35

KU/L	Simultaneous addition to four subzones	Sequential addition to one zone
0	0.048*	0.038*
0.5	0.053	0.047
2	0.085	0.074
10	0.286	0.256
50	1.334	1.291
200	2.507	2.487

* = scanning signal (Vmm)

Table 2 shows that the uptake is comparable for strips with discrete application zones in comparison with addition to a single zone. The experiment therefore shows that the same result may be obtained if addition is made simultaneously to the zone sequence LZ₄B, LZ₃R*, LZ₂B, LZ₁S as if sample, Reactant* and buffer are added sequentially to a common application zone.

EXAMPLE 3: SEQUENTIAL METHOD WITH THE ZONE SEQUENCE: LZ₅B, LZ₄R*, LZ₃B, LZ₂S, LZ₁B, DZ. DETECTION OF BIRCH-SPECIFIC hIgE IN TEST VARIANT WITH FLUORESCENT DETECTION CONJUGATE

Methods and materials

Extraction of birch pollen allergen t3, Betula verucosa: 1 part (weight) of birch pollen (Allergon, Sweden) was extracted with 10 parts (volume) of 0.1 M phosphate buffer, pH 7.4. The extraction was continued for 2 hours on a shaker table at +4 °C. The extract was centrifuged at 4000 rpm for 1.75 hours. After filtration, the solution was applied to a PD-10 column (Pharmacia Biotech AB) and eluted in 0.1 M NaHCO₃, pH 8.5. The t3 eluate (designated: t3 extract 1/14) was taken to amino acid analysis for determination of the total protein content.

Coupling of birch pollen allergen to polystyrene particle:

t3 extract was coupled to phenyldextran coated polystyrene particles (prepared according to Example 1) with CDAP. The coupling was effected analogously with the coupling of

5 hIgE.

Polystyrene particles (2128 mg) coated with phenyldextran in 30 % (by volume) acetone, 2 % particle suspension, were activated with 954 mg of CDAP (100 mg/ml in 30 % acetone)

10 and 7.63 ml of 0.2 M triethylamine (TEA, Riedel-de Haen, Germany). CDAP was added with stirring and TEA was added dropwise for 90 seconds and with stirring for totally 120 seconds. The reaction was stopped by the addition of 30 % acetone (4 times the volume) and centrifugation at 12,400 g

15 for 35 minutes. The particles were washed once with deionized water.

640 ml of t3 extract 1/14 in 0.1 M NaHCO₃, pH 8.5, were added to the activated particles, and coupling was

20 continued for 1 hour on a shaker table. After centrifugation, the particles were deactivated with 0.05 M aspartic acid and 0.05 M glutamic acid in 0.1 M NaHCO₃, pH 8.5. Incubation then took place on a shaker table overnight at +4 °C. The particles were then washed twice with 50 mM NaPO₄, 0.05 % NaN₃, pH 7.4. The particle concentration was determined spectrophotometrically at 600 nm with uncoated polystyrene particles as reference. t3-coupled polystyrene particles were taken to amino acid analysis for determination of the total protein content.

30

Deposition of t3-coupled polystyrene particles on a

membrane: To nitrocellulose sheets with polyester backing

(Whatman, 8 µm, 5 cm width) were applied zones of t3-

coupled particles diluted to 4 % particle content in 50 mM

35 NaPO₄, 10 % sucrose, 0.05 NaN₃, pH 7.4. The deposits were dried for 1 hour at 30 °C.

Zones for application of buffer, sample and detection

particle conjugate: Five 1 mm wide strips of adhesive tape (2 mils clear polyester, Arcare with glue on one side) were placed well separated from the zone containing the

5 deposited material and in parallel with the zone at a distance of 5 mm from each other. The tape strips thereby defined five different 5 mm wide zones. The sheets were cut perpendicularly to the zone containing deposited material to strips having a width of 0.5 cm (the length of the strip 10 then became 5 cm) (Singulator: Matrix 1201 membrane cutter, Kinematic automation). The final strips exhibited five zones (application zones) separated by tape strips as zone spacers and a separate zone with deposited birch pollen (detection zone). Strips without zone spacers, i.e. without 15 separated application zones, were prepared as a comparison.

Test methodology: Strips with separated application zones were mounted, and reagents were applied as in Example 2.

Buffer (20 μ L) was applied to the zone closest to the 20 application zone, and then serum sample (30 μ L), buffer (20 μ L), detection particle conjugate (20 μ L) and buffer (30 + 30 μ L) in the respective application zone located upstream. For sequential application to the strips without zone spacer 20 μ L of buffer were first applied to the lower end 25 of the strip, and after sucking in thereof, 30 μ L of sample were applied in the same position and then buffer (20 μ L), fluorescent particle conjugate (20 μ L) and buffer (30 + 30 μ L). Before all applications, the preceding application had been sucked in by the strip. The detection particle 30 conjugate and the buffer were according to Example 2.

Results:

With the application zone consisting of five subzones and with simultaneous addition thereto, it turned out that the 35 liquids, precisely as in the Examples above, migrated out of the application zone in the existing order. The time

required for a whole test with simultaneous addition was about 21 minutes, and the time needed for a whole test with sequential addition was about 27 minutes.

5 **Table 3:** Analysis results from runs with sequential addition in one zone and from simultaneous addition in 4 subzones (buffer, analytically detectable reactant, buffer, sample).

	Simultaneous addition to 5 subzones	Sequential addition to 1 zone
neg	0.067*	0.058*
pos 1	1.911	2.608
pos 2	0.299	0.375

10

* = scanning signal (Vmm)

Table 3 shows that the uptake is decreased to some extent for strips having discrete application zones compared with 15 addition to a single zone. The decrease is, however, marginal and is probably due to the fact that the flow rate in simultaneous application was somewhat delayed. The experiment therefore demonstrates that basically the same results may be achieved for simultaneous application to the 20 zone sequence LZ₅B, LZ₄R*, LZ₃B, LZ₂S, LZ₁B as if sample, Reactant* and buffer are applied sequentially to a common application zone.

CLAIMS

1. A method for determination of an analyte in a sample in a flow matrix by use of a transport flow of one or more biospecific affinity reactants, at least one of which is analytically detectable (Reactant*) and one is firmly anchored in the matrix (Reactant I), and the flow matrix comprises:

10 A) an application zone for liquid (LZ), containing buffer and sample and optionally one or more of the reactants, but not Reactant I,

15 B) a detection zone (DZ) located downstream of LZ with the firmly anchored reactant (Reactant I), and

C) optionally one or more zones in which any of the reactants has been pre-deposited,

20 wherein (i) the flow towards the detection zone is initiated by addition of the liquid with sample in the application zone LZS for transport of analyte and reactants towards the detection zone (DZ), and (ii) the amount of Reactant* bound to DZ is detected, the detected amount

25 being related to the amount of analyte in the sample,
characterized in that

I. the flow matrix comprises at least two application zones for liquid arranged substantially adjacent to each other:

30

LZ_m . . . LZ_n . . . LZ₁ DZ
----->

wherein

35

a) LZ_n is an application zone for liquid, and n is the position of the application zone LZ_n,

b) m is the total number of application zones in which flow is initiated ($m \geq 2$),

5 c) one LZ_n is an application zone for sample (LZ_n, S) and one LZ_n is for Reactant* (LZ_n, R^*) with $n'' \geq n'$,

d) -----> is the direction of the flow, and

10 e) DZ is the detection zone, and

II. flow is initiated by adding liquid to each zone LZ_m . . . LZ_n . . . LZ_1 in such a way that liquid_{n+1}, added to the application zone LZ_{n+1} , is transported through the matrix immediately after liquid_n, added to the nearest 15 downstream application zone LZ_n .

2. The method according to claim 1, **characterized** in that $n'' > n'$ (sequential variants regarding analyte and Reactant*).

20 3. The method according to claim 1, **characterized** in that $n'' = n'$ (simultaneous variants regarding analyte and Reactant*).

25 4. The method according to any of the claims 1 - 3, **characterized** in that Reactant* is pre-deposited in its application zone (LZ_n, R^*) .

5. The method according to any of the claims 1 - 4, 30 **characterized** in that liquid_{n+1} is added to LZ_{n+1} before or substantially simultaneously with adding liquid_n to LZ_n , with the exception of $n = m$, which zone lacks the zone LZ_{n+1} .

6. The method according to any of the claims 1 - 5, **characterized** in that LZ_{n+1} finishes where LZ_n starts, with the exception of $n = m$, which zone lacks the zone LZ_{n+1} .

5 7. The method according to any of the claims 1 - 6, **characterized** in that application of liquid is performed substantially simultaneously in all $LZ_m . . . LZ_n . . . LZ_1$.

8. The method according to any of the claims 1 - 7, 10 **characterized** in that $m \leq 6$; n' is 1, 2 or 3; $n'' > n'$; $LZ_{n'+1}$, $LZ_{n'+2}$, $LZ_{n'+3}$, $LZ_{n'-1}$, and $LZ_{n'-2}$ are application zones for liquids intended for transport of Reactant* or other reactant or buffer without reactant, as far as allowed by m , n'' and n' .

15 9. The method according to any of the claims 1 - 8, **characterized** in that at least one of the zones $LZ_m . . . LZ_n . . . LZ_1$ comprises a pad or material layer applied on the flow matrix.

20 10. The method according to any of the claims 1 - 8, **characterized** in that the zones $LZ_m . . . LZ_n . . . LZ_1$ have zone spacers between each other.

25 11. The method according to any of the claims 1 - 10, **characterized** in that the composition of transported components from an application zone LZ_n is not the same as from the nearest adjacent application zone LZ , in which flow is initiated, (LZ_{n+1} and LZ_{n-1} , with the exception of $n = m$ and $n = 1$, which zones lack LZ_{n+1} and LZ_{n-1} , respectively).

12. The method according to any of the claims 1 - 11, **characterized** in that at least one reactant, other than 35 Reactant*, is pre-deposited in an application zone $LZ_n . . . R$ for liquid intended for transport of the reactant.

13. The method according to any of the claims 1 - 12, **characterized** in that $m \leq 6$ and that n' for the application zone for sample (LZ_n, S) is 1, 2 or 3.

5

14. The method according to any of the claims 1 - 13, **characterized** in that Reactant* has biospecific affinity for the analyte so that Reactant* is incorporated into a complex Reactant'---Analyte---Reactant* in the detection zone in an amount related to the amount of analyte in the sample, in which complex Reactant' has biospecific affinity to the analyte and is

15

(a) Reactant I, or

(b) a reactant to which Reactant I exhibits biospecific affinity and which is transported from LZ_n, S or from an application zone downstream of LZ_n, S .

20

15. The method according to any of the claims 1 - 14, **characterized** in that the matrix comprises at least one calibrator zone (CZ), in which calibrator is bound to, or in advance has been bound to the matrix.

25

16. The method according to claim 15, **characterized** in that the calibrator zone or zones (CZ) have a binder for the calibrator firmly anchored in the matrix, the calibrator optionally being pre-deposited in the matrix upstream of the calibrator zone or zones.

30

17. The method according to any of the claims 1 - 16, **characterized** in that

- a. the analyte is chosen among antigens generally, and
- b. the method is performed as part of diagnosing allergy or autoimmune disease.

35

18. A device for determination of an analyte in a sample in a flow matrix by use of a transport flow of one or more biospecific affinity reactants, at least one of which is analytically detectable (Reactant*) and one is firmly 5 anchored in the matrix (Reactant I), said device comprising a flow matrix having:

10 A) an application zone for liquid (LZ), containing buffer and sample and optionally one or more of the reactants, but not Reactant I,

15 B) a detection zone (DZ) located downstream of LZ with the firmly anchored reactant (Reactant I), and

20 C) optionally one or more zones in which any of the reactants has been pre-deposited,

characterized in that

25 the flow matrix comprises at least two application zones for liquid arranged substantially adjacent to each other:

LZ_m . . . LZ_n . . . LZ₁ DZ
----->

30

wherein

a) LZ_n is an application zone for liquid, and n is the position of the application zone LZ_n,

30 b) m is the total number of application zones in which flow is initiated (m ≥ 2),

c) one LZ_n is an application zone for sample (LZ_n, S) and 35 one LZ_n is for Reactant* (LZ_n, R*) with n'' ≥ n',

d) -----> is the direction of the flow, and

e) DZ is the detection zone.

19. The device according to claim 18, **characterized** in
5 that $n'' > n'$ and that the device is intended for
sequential transport of analyte and Reactant*.

20. The device according to claim 18, **characterized** in
that $n'' = n'$ and that the device is intended for
10 simultaneous transport of analyte and Reactant*.

21 The device according to any of the claims 18 - 20,
characterized in that Reactant* is pre-deposited in its
application zone (LZ_n, R^*).

15 22. The device according to any of the claims 18 - 21,
characterized in that LZ_{n+1} finishes where LZ_n starts, with
the exception of $n = m$, which zone lacks the zone LZ_{n+1} .

20 23. The device according to any of the claims 18 - 22,
characterized in that $m \leq 6$; n' is 1, 2 or 3; $n'' > n'$;
 $LZ_{n'+1}$, $LZ_{n'+2}$, $LZ_{n'+3}$, $LZ_{n'-1}$, and $LZ_{n'-2}$ are application zones
for liquids intended for transport of Reactant* or other
reactant or buffer without reactant, as far as allowed by
25 m , n'' and n' .

24. The device according to any of the claims 18 - 23,
characterized in that the zones $LZ_m . . LZ_n . . LZ_1$ have
zone spacers between each other.

30 25. The device according to any of the claims 18 - 23,
characterized in that at least one of the zones
 $LZ_m . . LZ_n . . LZ_1$ comprises a pad or material layer
applied on the flow matrix.

26. The device according to any of the claims 18 - 25, **characterized** in that at least one reactant, other than Reactant*, is pre-deposited in an application zone LZ_{n...R} for liquid intended for transport of the reactant.

5

27. The device according to any of the claims 18 - 26, **characterized** in that m ≤ 6 and that n' for the application zone for sample (LZ_{n,S}) is 1, 2 or 3.

10 28. The device according to any of the claims 18 - 27, **characterized** in that the detection zone DZ comprises firmly anchored Reactant I, and that a reactant to which Reactant I exhibits biospecific affinity optionally is pre-deposited in LZ_{n,S} or in an application zone downstream of
15 LZ_{n,S}.

29. The device according to any of the claims 18 - 28, **characterized** in that the flow matrix comprises at least one calibrator zone CZ, in which a calibrator or a binder
20 for the calibrator is firmly anchored in the matrix.

30. The device according to claim 29, **characterized** in that the calibrator zone or zones (CZ) have a binder for the calibrator firmly anchored in the matrix, and that
25 calibrator optionally is pre-deposited in the matrix upstream of the calibrator zone or zones.

31. The device according to any of the claims 18 - 30, **characterized** in that the device is intended for diagnosing
30 allergy or autoimmune disease.

32. A test kit, **characterized** in that the kit comprises (i) a device according to any of claims 18 - 29 and (ii) Reactant*.

33. The test kit according to claim 32, **characterized** in that the kit additionally comprises (iii) a calibrator when a binder for the calibrator is firmly anchored in the matrix.

DECLARATION
and
POWER OF ATTORNEY

U.S. NATIONAL PHASE OF INTERNATIONAL APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **Analytical Method Comprising Addition in Two or More Positions and a Device and Test Kit Therefor**, the specification of which was filed as International Application No. PCT/SE98/02463 on December 30, 1998,

and was amended under Article 19 on _____.
 (if applicable)

and was amended under Article 34 on _____.
 (if applicable)

and was assigned U.S. Application Serial No. 09/582,734, and was amended on June 30, 2000.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits and/or U.S. Provisional application priority benefits under Title 35, United States Code, §119 of any foreign application(s) or U.S. Provisional applications for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign and U.S. Provisional Application(s)			Priority Claimed	
Number	Country	Day/Month/Year Filed	Yes	No
9704934-0	Sweden	December 30, 1997	X	

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulation, §1.56(a) which occurred between the filing date of the prior application and the PCT international filing date of this application:

(Application Serial No.) (Filing Date)	(Status) (patented, pending, abandoned)
--	---

I hereby appoint Holly D. Kozlowski, Registration No. 30,468; Ronald J. Snyder, Registration No. 31,062; James D. Liles, Registration No. 28,320; Lynda E. Roesch, Registration No. 29,696; Martin J. Miller, Registration No. 35,953; Anne B. Pellet, Registration No. 37,781; Jackie A. Zurcher, Registration No. 42,251; John V. Harmeyer, Registration No. 41,815; Scott N. Barker, Registration No. 42,292; Geoffrey L. Oberhaus, Registration No. 42,955; Joseph P. Mehrle, Registration No. 45,535; John P. Colbert, Registration No. 45,765; and Stephen S. Wentsler, Registration No. 46,403, c/o Dinsmore & Shohl, 1900 Chemed Center, 255 East Fifth Street, Cincinnati, Ohio 45202 (513) 977-8200, my attorneys, with full power in each of them, of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

The undersigned hereby authorizes the above-named U.S. attorneys to accept and follow instructions from Pharmacia & Upjohn AB as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the undersigned and the aforementioned U.S. attorneys. In the event of a change in the firm or persons from whom instructions may be taken, the aforementioned U.S. attorneys will be so notified in writing by the undersigned.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Ib MENDEL-HARTVIG

Inventor's signature

 29/8 2008

Date

Residence: Rabeniusvägen 28, S-756 55 Uppsala, Sweden 

Citizenship: Sweden

Post Office Address: Rabeniusvägen 28, S-756 55 Uppsala, Sweden

Full name of second inventor: Ilya ZELIKMAN

Inventor's signature

000914

Date

Residence: Skymningsvägen 56, S-743 32 Storvreta, Sweden ~~SE~~

Citizenship: Sweden

Post Office Address: Skymningsvägen 56, S-743 32 Storvreta, Sweden

Full name of third inventor: Gerd RUNDSTRÖM

Inventor's signature

00 08 29

Date

Residence: Bruksvägen 16, S-752 41 Uppsala, Sweden ~~SE~~

Citizenship: Sweden

Post Office Address: Bruksvägen 16, S-752 41 Uppsala, Sweden

591443.01